Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Ca...

OBJECTIVE RESPONSE AT LOW DOSE IN THE FIRST-IN-HUMAN IMMUNICY-1 TRIAL EVALUATING NON-GENE EDITED ALL...

LEccho Aujourdhui à 03:00Quelques informations récoltées en coulisses...Patrick Jean...

The alloSHRINK study has been updated on Novembre 20. See the Clinical Trial Site in the US with the...

These are the main takeaways found mainly in the last 5 minutes of this long interview. Bringing...

celyad.com/wp-content/uploads/2021/06...celyad.com/wp-content/uploads/2021/06...

Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 Trial of shRNA-based Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Associatio...

Treatment with CYAD-211 generally well-tolerated at first two dose levels, with no evidence of Graft-versus-Host Disease observedTwo partial responses observed among five evaluable patientsCell en...

Please see the table showing the results as of 25/2/2021 showing 1 SD and 1 PR over 2 patients at first dose level (Response for the 3rd patient was not available at that time.... may be good news to ...

OBJECTIVE RESPONSE AT LOW DOSE IN THE FIRST-IN-HUMAN IMMUNICY-1 TRIAL EVALUATING NON-GENE EDITED ALLOGENEIC CYAD-211 ANTI-BCMA CAR-T PRODUCT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMAAuthor(s): Seba...

Two years after spelling out its off-the-shelf Car-T ambitions Celyad has some early human data to go on. A presentation at the upcoming European Hematology Association meeting is set to detail the fi...

quote:Twin schreef op 9 juni 2021 07:49:Speedbull schreef voor 9 juni results, of begrijp ik verkeerd? Hi Twin and others. What I ment is that the EHA2021 Virtual Congress will...

I red somewhere that Celyad will concentrate in the future mainly on Allogeneic approaches. They may try to create or fond a partnership for the autologous approach represente...

Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virt...

LEccho Aujourdhui à 03:00Quelques informations récoltées en coulisses...Patrick Jeanmart va travailler à nouveau avec Christian Homsy. Directeur financier de Celyad Oncology pendant on...

celyad.com/wp-content/uploads/2020/12...

Here are the links of the 3 posters presented at ASH2020The 3rd link shows great potential for CYCLE-1 see below conclusionsCONCLUSIONS? Preliminary clinical activity data showed anti-leukemic...

IMMUNICY (cyad-211 BCMA) trial just started at UZ Antwerpen.www.clinicaltrials.gov/ct2/show/NCT04...

New job recruitment since 26/11 = Procurement and supply chain Manager in Belgium.This mens that the manufacturing site is (or will soon) be operational in Belgium...

Celyad issued the corporate presentation for November.Here is the link.celyad.com/wp-content/uploads/2020/11...

Very good article: CAR-T cells were first tried against B-cell malignancies with CD19 used as a target antigen, resulting in remarkable clinical responses in diseases that were multiply rela...

Comments: CYAD-211 this is an intriguing development I think is well worth watching out for biotechstrategyblog.com/2020/11/ash20...

Livestream from NYlivestream.com/accounts/27896496/even...

www.nasdaq.com/events/celyad-oncology...

The alloSHRINK study has been updated on Novembre 20. See the Clinical Trial Site in the US with the addition of a test site in the US (= The Moffit Cancer Center Tampa, Florida, United States) with t...

Kepler Cheuvreux geeft koopadvies voor Celyad20 november 2020 Guruwatch.nlKepler Cheuvreux geeft koopadvies voor Celyad met een koersdoel van 13,40 Lees meer.....

Fact sheet - see Celyad sitecelyad.com/wp-content/uploads/2020/11...

These are the main takeaways found mainly in the last 5 minutes of this long interview. Bringing manufacturing back within Celyad is a key and important technical decision to speed-up changes and ...

New interview from David Gilham 18/11/2020podcasts.google.com/feed/aHR0cHM6Ly9h...

As compared to CYAD-01, CYAD-02 cell expansion in vitro was 3-fold increased. See the schedule at the bottom of this linkashpublications.org/blood/article/136...

Clinical trial IMMUNICY has been posted on the afmps site for 3 clinical sites in Belgium (AZ Delta, UZ Antwerpen, Jules Bordet) with a starting date of 31/8/2020banquededonneesessaisclini...

Publication in BLOOD703.ADOPTIVE IMMUNOTHERAPY: MECHANISMS AND NEW APPROACHES| NOVEMBER 5, 2020Clinical Development of a Non-Gene-Edited Allogeneic Bcma-Targeting CAR T-Cell Product in Relapsed ...

Milestones: Accelerate the clinical development of CYAD-01 for the treatment of r/r AML and focus on path to commercializationNext generation non gene edited shRNA-based allogeneic CARs (CYAD-200 se...

Celyad well placed in the race on allogenicSee the bottom of the diagramtwitter.com/Varro_Analytics/status/13...

IMMUNICY-1 = new clinical trial for CYAD-211Study Type : Interventional (Clinical Trial)Estimated Enrollment : 12 participantsIntervention Model: Sequential AssignmentMasking: None (Open ...

Presentatie van Peggy Sotiroupoulouvimeo.com/469787769...

celyad.com/wp-content/uploads/2020/10...

CELYADFilippo Petti, CEOMont-Saint-Guibert, Belgium(NASDAQ: CYAD)Celyad is a clinical-stage biopharmaceutical company focused on the development of CAR-T cell based therapies. The company’s le...

ShRNA and Single Genetic Modification May Lower CAR-T Manufacturing CostsCelyad technology discussed with David Gilhamwww.genengnews.com/topics/bioprocessi...

Celyad Oncology discusses Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy - Peggy Sotiropoulou Ph.D. -..https:/...

Nkarta filed for a $100M #IPO- Allogeneic, off-the-shelf engineered NK #CellTherapy- Leads target NKG2D and CD19- $125M raised to date- Investors include RA, @NEA, $NVO, $GSK SR One, Samsa...

In this @oncologytube video, chief scientific officer of @CelyadSA Dr. David Gilham discusses how single vector multiplexed shRNA provides a non-gene edited strategy to alter #gene expression in CAR T...

Hi Twin, Yes, this is really a good news which seems to prove that CYAD-02 is working quite well within the Belgian sites; otherwise why should a so prestigious Cancer Center in the US requesting the ...

Het Britse farmabedrijf AstraZeneca heeft zijn Amerikaanse concurrent Gilead benaderd over een mogelijke fusie. Dat meldt het financieel persbureau Bloomberg op basis van ingewijden.Als het inderdaa...

ASCO 2020: Celyad’s Off the Shelf CAR-T Cell Therapy Shows Promise against Colorectal CancerThis data shows that there is a possibility of host vs. graft response leading to the rapid clearance of t...

The Investor Document for June 2020 has been relased on Celyads site under the tab investors at the bottom right of the page...

Conference call - What is to remember?Om 45:00 minuut zegt Frdric +/- dit: Ik wil herhalen in de globale context van deze klinische proef (voor degenen die niet bekend zijn met de ...

Some reading for you allCelyad on pages 11 to 13en.calameo.com/read/006113385ee6a76ce...

5 Health Care Stocks to Bet on as Coronavirus Woes LingerZacks Sreoshi Bera Zacks May 27, 2020Celyad SA CYAD, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell...

@COVID_Evidence27 marsClinicalTrials.gov: A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19: Condition: COVID-19 Intervention: Biolo...

Journal of Cancer Research and Immuno-Oncology@immunooncolImmunotherapy using young cells offers promising option against cancer. These #NK cells appear to be more effective the earlier...

Celyad kondigt aan dat het op de avond van dinsdag 24 maart 2020, de financile en operationele resultatenvan het hele jaar 2019 zal rapporteren.Na de persmededeling, zal het Celyad managemen...

@Noob nr1LSP has decided to postpone this week’s BioCapital Europe until later in the year in light of the growing concerns over the spread of the COVID – 19 virus across Europe and increasing numbe...

Proposition of resolution: The general meeting decides to modify the articles of association of theCompany to modify the social denomination of the Company from “Celyad” to “Celyad Oncology”...

Curriculum Vitae of new proposed member of the Board – Maria KoehlerDr Maria Koehler, Ph.D., is a hematologist/oncologist with a successful academic careerand more than 20 years of experience in b...